RT Journal Article
SR Electronic
T1 A nationwide joint spatial modelling of simultaneous epidemics of dengue, chikungunya, and Zika in Colombia
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.10.25.24316124
DO 10.1101/2024.10.25.24316124
A1 Picinini Freitas, Laís
A1 Carabali, Mabel
A1 Schmidt, Alexandra M.
A1 Salazar Flórez, Jorge Emilio
A1 Ávila Monsalve, Brayan
A1 García-Balaguera, César
A1 Restrepo, Berta N.
A1 Jaramillo-Ramirez, Gloria I.
A1 Zinszer, Kate
YR 2024
UL http://medrxiv.org/content/early/2024/10/27/2024.10.25.24316124.abstract
AB Background Chikungunya, and Zika emerged in the 2010s in the Americas, causing simultaneous epidemics with dengue. However, little is known of these Aedes-borne diseases (ABDs) joint patterns and contributors at the population-level.Methods We applied a novel Poisson-multinomial spatial model to the registered cases of dengue (n=291,820), chikungunya (n=75,913), and Zika (n=72,031) by municipality in Colombia, 2014-2016. This model estimates the relative risk of total ABDs cases and associated factors, and, simultaneously, the odds of presence and contributors of each disease using dengue as a baseline category. This approach allows us to identify combined characteristics of ABDs, since they are transmitted by the same mosquitoes, while also identifying differences between them.Findings We found an increased ABDs risk in valleys and south of the Andes, the Caribbean coast, and borders, with temperature as the main contributor (Relative Risk 2.32, 95% Credible Interval, CrI, 2.05-2.64). Generally, dengue presence was the most probable among the ABDs, although that of Zika was greater on Caribbean islands. Chikungunya and Zika were more likely present than dengue in municipalities with less vegetation (Odds Ratio, OR, 0.75, 95%CrI 0.65-0.86, and 0.85, 95%CrI 0.74-0.99, respectively). Chikungunya tended to be present in more socially vulnerable areas than dengue (OR 1.20, 95%CrI 0.99-1.44) and Zika (OR 1.19, 95%CrI 0.95-1.48).Interpretation Important differences between the ABDs were identified and can help guide local and context-specific interventions, such as those aimed at preventing cases importation in border and tourism locations and reducing chikungunya burden in socially vulnerable regions.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by a grant from the Canadian Institutes of Health Research [grant number 428107]. Mabel Carabali holds a Fonds de recherche du Qué bec - Santé (FRQS) Chercheur Boursier Junior 1 [329874]. Alexandra M. Schmidt acknowledges financial support from the Natural Sciences and Engineering Research Council (NSERC) of Canada (Discovery Grants) [RGPIN-2024-04312]. Kate Zinszer holds a FRQS Chercheur Boursier Junior 2 [310728]. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Science and Health Research Ethics Committee (Comité d′é thique de la recherche en sciences et en santé - CERSES) of the University of Montreal, approval number CERSES-19-018-D.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe data used in this study are secondary data and are publicly available. Cases data are available at the Colombian National Public Health Surveillance System (Sistema Nacional de Vigilancia en Salud Pública - SIVIGILA) website (http://portalsivigila.ins.gov.co/). Environmental data was organised and made available by Siraj et al. (2019) (https://doi.org/10.5061/dryad.83nj1). Population and socioeconomic data are available at the National Administrative Department of Statistics of Colombia (Departamento Administrativo Nacional de Estadística - DANE) website (https://www.dane.gov.co/). A version of the healthcare access indexes can be found at the Colombian National Health Observatory (Observatorio Nacional de Salud - ONS) website (https://www.ins.gov.co/Direcciones/ONS/). Codes for the model are available at https://github.com/laispfreitas/joint_DZC_model.